Web Exclusives

Rheumatology Practice Management (RPM) will be providing a valuable new resource to our readers. Beginning in June, we will be featuring a Coding Corner section, with the goal of helping practice managers stay informed of pertinent issues concerning medical billing and coding, denials, and appeal protocols.

Read Article ›

In the coming year, NORM and Rheumatology Practice Management will strive to provide practice managers with the information and resources they need to deliver quality patient care.

Read Article ›

The US Food and Drug Administration (FDA) has approved etanercept-szzs, a biosimilar to etanercept (Enbrel), for the treatment of multiple inflammatory diseases, according to an announcement by the organization. The biosimilar injection has been approved to treat patients with moderate-to-severe rheumatoid arthritis; moderate-to-severe polyarticular juvenile idiopathic arthritis; active psoriatic arthritis; active ankylosing spondylitis; and chronic, moderate-to-severe plaque psoriasis. Read Article ›

In our last issue, we discussed ways for rheumatology practice managers, physicians, healthcare professionals, and patients to get involved and raise awareness about concerns surrounding the Medicare Part B Drug Payment Model Proposed Rule by the Centers for Medicare & Medicaid Services (CMS). Andrea and I wanted to share our Washington, DC, experience and encourage our membership to continue to oppose the Part B Drug Demonstration Project. Read Article ›

Immediate-release opioid analgesics will now require boxed warnings regarding the serious risks for abuse, addiction, overdose, neonatal opioid withdrawal syndrome (NOWS), and death associated with the drugs, according to an announcement by the US Food and Drug Administration (FDA). This is the latest in a number of steps recently outlined by the FDA in their bid to reassess their approach to opioid medications. Read Article ›

Ixekizumab (Taltz) has been approved by the US Food and Drug Administration (FDA) for use in patients with moderate-to-severe plaque psoriasis, the agency has announced. Administered as an injection, ixekizumab is an antibody that binds and inhibits the inflammatory response of the inflammation-causing interleukin-17A protein. Read Article ›

The US Food and Drug Administration (FDA) announced the approval of Inflectra (infliximab-dyyb)—a biosimilar to Remicade (infliximab)—for patients with chronic severe plaque psoriasis, and active ankylosing spondylitis or psoriatic arthritis. The biosimilar is also indicated for adult patients with moderately to severely active ulcerative colitis who have inadequately responded to standard therapy; in combination with methotrexate for patients with moderately to severely active rheumatoid arthritis; and patients aged ≥6 years with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Inflectra is the second biosimilar approved by the FDA. Read Article ›

It is with great pleasure that I introduce all of our valued readers to Ethel Owen, the new Editor-in-Chief of Rheumatology Practice Management (RPM). I have known Ethel for many years and she has been instrumental in my growth as a rheumatology practice manager. Her qualifications make her a perfect choice for the Editor-in-Chief position. I look forward to serving on her editiorial board. Read Article ›

A smart investor needs to fully comprehend how risk is measured and its potential effect on long-term portfolio performance. This article outlines 5 principles of investment management that can increase your chance of success. Read Article ›

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib). Read Article ›

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments. Read Article ›

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Read Article ›

Page 3 of 5

Subscribe to
Urology Practice Management

Stay up to date with urology news & updates by subscribing to recieve the free UPM print publications or weekly e‑Newsletter.

I'd like to recieve: